ReviewTherapeutic advances in cardiovascular disease2016
Drug discovery in renin-angiotensin system intervention: past and future.
Review in Therapeutic advances in cardiovascular disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 33 citations in OpenAlex.
- Inhibition of dimeric SARS-CoV-2 Mpro displays positive cooperativity and a mixture of covalent and non-covalent binding.iScience · 2025Article
- Breaking new ground in heart failure management: novel therapies and future frontiers.Frontiers in cardiovascular medicine · 2025Review
- Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review.International journal of molecular sciences · 2021Review
- Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator.Acta pharmaceutica Sinica. B · 2021Review
- Inhibition of tanshinone IIA on renin activity protected against osteoporosis in diabetic mice.Pharmaceutical biology · 2020Article
- Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System.Viruses · 2020Article
- Effects of Olive Oil on Blood Pressure: Epidemiological, Clinical, and Mechanistic Evidence.Nutrients · 2020Review
- The Second Gaddum Lecture: its origins and outcomes.British journal of pharmacology · 2020Review
- Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.Bioscience reports · 2019Review
- Investigating the RAS can be a fishy business: interdisciplinary opportunities using Zebrafish.Clinical science (London, England : 1979) · 2018Review
- Selection for female traits of high fertility affects male reproductive performance and alters the testicular transcriptional profile.BMC genomics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The renin-angiotensin system (RAS) plays a central role in the control of blood pressure in the body and the way this interacts with other systems is widely recognized. This has not always been the case and this review summarizes how our knowledge has evolved from the initial discovery of renin by Tigerstedt and Berman in 1898. This includes the identification of angiotensin in the 1950s to the proposed relationship between this system, hypertension and ultimately cardiovascular disease. While the RAS is far more complex than originally thought, much is now known about this system and the wide ranging effects of angiotensin in the body. This has enabled the development of therapies that target the various proteins in this pathway and hence are implicated in disease. The first of these treatments was the angiotensin converting enzyme inhibitors (ACE-Is), followed by the angiotensin receptor blockers (ARBs), and more recently the direct renin inhibitors (DRIs). Clinical outcome trials have shown these drugs to be effective, but as they act at contrasting points in the RAS, there are differences in their efficacy and safety profiles. RAS blockade is the foundation of modern combination therapy with a calcium channel blocker and/or a diuretic given to reduce blood pressure and limit the impact of RAS activation. Other options that complement these treatments may be available in the future and will offer more choice to clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.